ClinicalTrials.gg
RecruitingNCT07561333Updated May 1, 2026

Comparing ACB+IPACK and ACB+BiFeS Block Combinations for Analgesia in Total Knee Arthroplasty

An interventional study of ACB+IPACK Group and ACB+BiFeS Group in Postoperative Pain and Total Knee Arthroplasty, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Hitit University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered Apr 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pain, Postoperative by Hitit University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Hitit University.

Planned enrollment
5th of 10
78 · median 74
Started
2025
with 2 others
No phase
10 of 10
4 open now
Registered
6th of 10
by date

Among the 10 studies in Pain, Postoperative by Hitit University, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 10 with no phase, and was the 6th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 10 studies in Pain, Postoperative by Hitit University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pain, Postoperative by Hitit University, or all of them as a file.
02

Study summary

Total knee arthroplasty (TKA) is associated with severe postoperative pain that delays mobilization, prolongs hospital stay, and reduces patient satisfaction. Regional analgesia techniques have gained prominence due to their opioid-sparing effects and favorable complication profiles compared to general anesthesia. While adductor canal block (ACB) effectively manages anterior knee pain with preserved motor function, posterior knee pain remains a challenge. IPACK (Infiltration between the Popliteal Artery and Capsule of the Knee) and the Biceps Femoris Short Head (BiFeS) block are techniques targeting posterior capsule innervation without causing motor block.This prospective study aims to compare the postoperative analgesic efficacy of ultrasound-guided ACB+IPACK versus ACB+BiFeS block combinations in patients undergoing TKA under spinal anesthesia. Patients (ASA I-III, age 18-80, BMI ≤35) will be randomized into two groups (n=39 each). Primary outcomes include NRS pain scores at rest and on movement, and opioid consumption at 0, 1, 3, 6, 12, 18, and 24 hours postoperatively. Secondary outcomes include time to first mobilization, motor block incidence, quadriceps muscle strength assessment, PONV, and quality of recovery (QoR-15).

Read the detailed description

Total knee arthroplasty (TKA) is a widely performed surgical intervention for end-stage knee osteoarthritis and other debilitating knee conditions. Severe postoperative pain following TKA delays early mobilization and rehabilitation, prolongs hospital stay, reduces patient satisfaction, and increases complication risk. Regional analgesia techniques have emerged as the preferred approach due to their ability to reduce opioid consumption, minimize opioid-related side effects (nausea, vomiting, respiratory depression, constipation), and preserve motor function. Ultrasound guidance further improves block success rates and reduces the local anesthetic volume required.

Optimal postoperative analgesia in TKA requires consideration of the complex innervation of the knee joint. The anterior compartment is primarily innervated by branches of the femoral nerve, while the posterior capsule is supplied by branches of the sciatic nerve. Adductor Canal Block (ACB) reduces anterior knee pain by blocking the saphenous nerve and branches of the obturator nerve while preserving quadriceps strength compared to femoral nerve block; however, it may be insufficient alone for controlling posterior capsule pain. The IPACK block (Infiltration between the Popliteal Artery and Capsule of the Knee) addresses posterior knee pain by depositing local anesthetic between the popliteal artery and knee capsule, blocking sensory innervation of the posterior capsule without causing motor block. The Biceps Femoris Short Head (BiFeS) block is a novel ultrasound-guided technique targeting nerve branches innervating the posterolateral knee capsule, aiming to reduce posterior knee pain while preserving motor function.

Study Design:

This is a prospective, randomized, observational study conducted at Hitit University Erol Olçok Training and Research Hospital. Patients will be randomized into two groups by an investigator not directly involved in the study:

Group P (ACB+IPACK): Adductor canal block combined with IPACK block (n=39) Group B (ACB+BiFeS): Adductor canal block combined with Biceps Femoris Short Head block (n=39)

Inclusion Criteria:

Patients scheduled for TKA surgery, ASA physical status I-III, hemodynamically stable, aged 18 years or older, BMI ≤35 kg/m², and who have signed the informed consent form.

Exclusion Criteria:

Revision TKA surgery, simultaneous bilateral TKA, BMI >40 kg/m², ASA 4-5, inability to perform NRS pain scoring, allergy to local anesthetics, pregnancy or breastfeeding, age \<18 or >80 years, uncontrolled anxiety, alcohol or drug dependency, neuromuscular or peripheral nerve disease, high-dose opioid use within 3 days prior to surgery, widespread chronic pain, diabetes mellitus, hepatic or renal insufficiency, coagulation disorders, anticoagulant use, or infection at the block needle insertion site.

Anesthetic and Block Technique:

All patients will receive standard anesthesia monitoring (non-invasive arterial blood pressure, heart rate, ECG, pulse oximetry) and IV access via a 20G catheter. Quadriceps muscle strength will be recorded before block application using the Medical Research Council (MRC) scale. Premedication will consist of midazolam 0.07-0.15 mg/kg and fentanyl 0.5 mcg/kg IV, with supplemental oxygen via face mask. All block procedures will be performed under standard sterile conditions.

Adductor Canal Block (ACB): With the patient in supine position and the hip in slight external rotation, a linear ultrasound probe is placed vertically at the midpoint between the patella and inguinal crease on the medial thigh. The femoral artery is identified in short-axis view and tracked medially until it appears deep to the sartorius muscle. A 10 cm peripheral nerve block needle is advanced in-plane, and 15 mL of 0.25% bupivacaine is injected around the femoral artery deep to the sartorius muscle, with negative aspiration confirmed every 5 mL.

IPACK Block: With the patient in prone position, a linear probe is placed over the popliteal crease to visualize the space between the popliteal artery and femoral condyles. A 10 cm needle is inserted in-plane from medial to lateral. After negative aspiration and hydrodissection with 1-2 mL of local anesthetic to confirm correct placement, 25 mL of 0.25% bupivacaine is injected with negative aspiration confirmed every 5 mL, distributed evenly between the initial needle tip position (2 cm lateral to the popliteal artery) and the posteromedial border of the femur.

BiFeS Block: With the patient in supine position and the knee in slight flexion, a linear ultrasound probe is placed transversely on the lateral surface of the distal third of the thigh. The biceps femoris short head muscle is identified along the linea aspera of the femur. The needle insertion point is determined at the level of the lateral supracondylar line of the femur, approximately 6-8 cm proximal to the lateral femoral epicondyle. A 10 cm needle is advanced in-plane from lateral to medial, targeting the plane between the biceps femoris short head and the lateral femoral cortex. After hydrodissection with 1-2 mL to confirm correct plane, 25 mL of 0.25% bupivacaine is injected slowly with negative aspiration confirmed every 5 mL.

Following block application, spinal anesthesia will be performed with the patient in sitting position. The L4-L5 interspace will be identified, and 12.5 mg of 0.5% hyperbaric bupivacaine will be administered intrathecally via a 25G spinal needle over 1 minute. Surgery will commence when Bromage score reaches 3 and sensory block level reaches T10.

Postoperative Management and Outcome Measures:

Postoperative analgesia will be standardized for all patients: IV paracetamol 1g every 8 hours and patient-controlled analgesia (PCA) with tramadol (bolus dose 10 mg, lockout interval 20 minutes, no basal infusion, maximum 400 mg/day). Rescue analgesia with IV fentanyl 25 mcg will be administered for NRS ≥4, with total dose recorded.

Pain assessment using the Numeric Rating Scale (NRS, 0-10) will be performed at rest and during active movement (sitting up from bed) at postoperative hours 0, 1, 3, 6, 12, 18, and 24 by a blinded nurse or pain monitoring team.

Quadriceps muscle strength will be assessed at postoperative hours 2 and 24 using the MRC scale (0-5), with the contralateral unoperated leg serving as the control reference. A score of 4 or above will be considered indicative of preserved motor function.

Additional outcomes recorded will include tramadol consumption at 0-1, 1-12, 12-24, and total 24 hours; time to first opioid requirement; PONV severity (PONV scale 1-4) with ondansetron 4 mg IV administered for PONV score ≥2; vital signs at postoperative hours 0, 1, 3, 6, 12, 18, and 24; Quality of Recovery (QoR-15) scores preoperatively and at postoperative hour 24; time to first oral intake, flatus, and defecation; and time to first assisted mobilization.

Study Termination Criteria:

NRS >7 for 4 consecutive hours despite tramadol therapy, inability to perform NRS assessment, or incomplete surgery.

03

Conditions studied

  • Postoperative Pain
  • Total Knee Arthroplasty

Browse trials for

Keywords

  • Total knee arthroplasty
  • Regional anesthesia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for primary total knee arthroplasty surgery
  • classification I-III
  • Hemodynamically stable
  • Age ≥ 18 years and ≤ 80 years
  • ≤ 35 kg/m²
  • Signed written form

Exclusion criteria

Exclusion Criteria:

  • Revision total knee arthroplasty surgery
  • Simultaneous bilateral total knee arthroplasty
  • > 40 kg/m²
  • classification 4-5
  • Inability to perform NRS pain scoring
  • Known allergy to local anesthetics
  • Pregnancy or breastfeeding
  • Age \< 18 or > 80 years
  • Uncontrolled anxiety disorder
  • Alcohol or drug dependency
  • Neuromuscular disease or peripheral nerve disease
  • High-dose opioid use within 3 days prior to surgery
  • Widespread chronic pain syndrome
  • Diabetes mellitus
  • Hepatic or renal insufficiency
  • Coagulation disorders
  • Current use of anticoagulant medications
  • Infection at the peripheral nerve block needle insertion site
  • Refusal to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    ACB+IPACK Group

    ACB+IPACK Group: Patients receiving ultrasound-guided adductor canal block (15 mL of 0.25% bupivacaine) combined with IPACK block (25 mL of 0.25% bupivacaine) for postoperative analgesia following total knee arthroplasty under spinal anesthesia.

    Procedure: ACB+IPACK Group

  • Active comparator
    ACB+BiFeS Group

    ACB+BiFeS Group: Patients receiving ultrasound-guided adductor canal block (15 mL of 0.25% bupivacaine) combined with Biceps Femoris Short Head block (25 mL of 0.25% bupivacaine) for postoperative analgesia following total knee arthroplasty under spinal anesthesia.

    Procedure: ACB+BiFeS Group

Interventions

  • ProcedureACB+IPACK Group

    Patients receiving ultrasound-guided adductor canal block (15 mL of 0.25% bupivacaine) combined with IPACK block (25 mL of 0.25% bupivacaine) for postoperative analgesia following total knee arthroplasty under spinal anesthesia.

  • ProcedureACB+BiFeS Group

    Patients receiving ultrasound-guided adductor canal block (15 mL of 0.25% bupivacaine) combined with Biceps Femoris Short Head block (25 mL of 0.25% bupivacaine) for postoperative analgesia following total knee arthroplasty under spinal anesthesia.

06

What researchers measure

Primary outcomes

  1. Cumulative 24-hour Opioid Consumption (Morphine Equivalent Dose)

    Total postoperative opioid consumption will be calculated as morphine-equivalent dose (mg) over the first 24 hours. Tramadol administered via patient-controlled analgesia (PCA) and rescue fentanyl (25 mcg IV for NRS ≥4) will be recorded and converted into morphine equivalents. The cumulative total opioid consumption at 24 hours will be reported.

    Time frame: 24 hours postoperative

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 1, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Nov 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07561333
Lead sponsor
Hitit University
Responsible party
Merve Yagiz Baldiran (Principal Investigator, Hitit University) — Principal investigator
First posted
May 1, 2026
Start date
Oct 1, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
May 1, 2026

Study contacts

Merve YAGIZ BALDIRAN, MD
Contact
merveyagiz-1@hotmail.com
+905432835144
Arzu AKDAGLI EKICI, MD
Contact
akekici@gmail.com
+905057516387
Guvenc DOGAN, MD
study chair · Hitit University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion